Compare Cassava Sciences Inc (FLNA) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Plby Group Inc — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Plby Group Inc is far larger — about 3× Cassava Sciences Inc's market cap, and Plby Group Inc is more actively traded (919,783 versus 759,018). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Plby Group Inc for 24 Days on average.
| FLNA | PLBY | |
|---|---|---|
Market Cap | $39.40M | $118.21M |
Volume | 759,018 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $2.71 |
52-Week Low | $0.68 | $0.99 |
Typical Hold Time | 37 Days | 24 Days |
Enterprise Value | -$43.28M | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
PLBY trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $12.67 million in 2025, though revenue grew to $120.93 million and the net loss narrowed significantly from prior years. Recent news highlights leadership appointments aimed at driving brand growth. The stock has a high P/E ratio of 49.34 but a reasonable P/S of 0.87, and analyst consensus is strongly bullish with 75% buy ratings.
The outlook is mixed: improving profitability trends and positive analyst sentiment offer potential upside, but high debt levels, negative shareholder equity, and bearish technicals pose significant risks. Investors should weigh the company's growth initiatives against its financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
